The ASAP Act would provide a pathway for Medicare coverage of blood-based biomarker screening tests for Alzheimer’s disease and related dementias, expanding access to early detection and diagnosis for patients and families.
Pass the ASAP Act to provide a pathway for Medicare coverage of blood-based biomarker screening tests for Alzheimer's disease and related dementias, expanding access to early detection and diagnosis.
Occurrences
Evidence
legacy_unverified · Source version not recorded · locator unknown
Congress.gov lists Rep. Vern Buchanan as the sponsor, says H.R. 6130 has the status "Introduced," and gives the latest House action as referral on 11/19/2025 to Energy and Commerce and Ways and Means. The tracker still shows later steps as Passed House, Passed Senate, To President, and Became Law.
legacy_unverified · Source version not recorded · locator unknown
Buchanan's office said the ASAP Act "currently has nearly 200 cosponsors" and "would provide a pathway for Medicare coverage of blood-based biomarker screening tests"; it also described advocates calling on Congress to "get the bill across the finish line."
Assessments
The promised outcome is passage of the ASAP Act and Medicare coverage pathway for blood-based dementia screening tests. Buchanan sponsored H.R. 6130 in the 119th Congress, and the bill has substantial cosponsor and advocacy support, but the official legislative status remains Introduced/referred to committee, with no House passage, Senate passage, presentment, or enactment. Because Buchanan is still in federal office and the Congress is ongoing, this is not a failed promise yet; it remains pending with clear effort.